•   
  •   
  •   

Entertainment Bayer not affected: CureVac produces less vaccine and announces partners

19:30  14 september  2021
19:30  14 september  2021 Source:   ksta.de

Fact check: Pfizer, Moderna and Johnson & Johnson COVID-19 vaccines all passed animal testing

  Fact check: Pfizer, Moderna and Johnson & Johnson COVID-19 vaccines all passed animal testing Each of the three COVID-19 vaccines approved for use in the U.S. passed animal testing studies. Claims otherwise are false.Now some proponents of the anti-parasitic drug traditionally used for animals are falsely claiming COVID-19 vaccinations haven't passed animal studies.

The biotech company CureVac reduces the production network due to the lower demand for its Corona vaccine. The contracts with Wacker Chemie as well as Celonic would be terminated, the company announced on Tuesday in Tübingen.

Das Tübinger Unternehmen Curevac wird seinen neuen Impfstoff nach der Zulassung auch bei Bayer in Wuppertal produzieren lassen. © Picture Alliance / DPA The Tübingen company CureVac will also produce its new vaccine after approval at Bayer in Wuppertal. Reaction to lower demand

The decision is a response to lower short-term peak demand for vaccines following the first wave of pandemic vaccine efforts, it was said. This has led to a further "changed demand" according to Curevacs Covid-19 vaccine candidates of the first generation (CVNCOV). This is currently reviewed by the European Drug Authority (EMA).

More than 40% of Americans may not get a flu shot this year. That could spell trouble during COVID.

  More than 40% of Americans may not get a flu shot this year. That could spell trouble during COVID. The main reason cited for not getting a flu shot is a belief that it isn't effective. Experts say flu shots prevent thousands of deaths every year.Last year's worries around a "twindemic" of influenza and COVID-19 overwhelming hospitals around the nation luckily went unfounded after a historically mild flu season.

Whether the EMA is allowed the vaccine is further open. At the end of June, CureVac announced that the effectiveness of his vaccine candidate CVNCOV was lower than the other vaccines. The Tübingen biotech company was assumed at the beginning of July that EMA will allow the vaccine to allow despite low efficacy. According to a final analysis, the CureVac preparation had shown an efficacy of 48 percent against a Covid-19 disease across all age groups.

No financial details

Financial details on the consequences of the terminated production partnerships not called CureVac. The contracts with Rentschler Biopharma and Novartis remained. CVNCOV will continue to be examined by the European Drug Authority, it continued. In the fourth quarter, a study on CV2COV should also begin, a second-generation Covid-19 vaccine candidates developed together with GlaxosmithKline.

US deaths in September outpacing previous months; U.N. General Assembly relying on vaccine honor system ahead of meeting: COVID-19 updates

  US deaths in September outpacing previous months; U.N. General Assembly relying on vaccine honor system ahead of meeting: COVID-19 updates The United States is on track to exceed the total number of COVID deaths in July and August combined within a matter of days. Live updates.Through Saturday, the country reported 32,526 deaths in September, compared to 27,612 in all of August. With deaths averaging nearly 2,000 per day, the U.S. is on track to exceed the total deaths of July and August combined within a matter of days, a USA TODAY analysis of data from Johns Hopkins University shows.

What the announcement for cooperation with the Leverkusen Bayer Group means the CureVAC message initially opened. The company is currently equipping its Wuppertal plant for the production of the CureVac vaccine. In the coming year, the Leverkusen want to produce 160 million doses of CVNCOV there.

Wuppertal remains important

This plan is now not endangered, it was on request from the "Kölner City-Anzeiger": "Our cooperation and service contract with Bayer says," said a CureVac spokeswoman: "Bayer is a strategic partner Cureevacs and not part of the external production network, which we have established in the course of the joint efforts to combat CVNCOV's most important manufacturing steps. "

The statements suggest that the Wuppertal Bayer work probably also in case of non-admission of the Corona vaccine from CureVac will be used in the future for the manufacture of other mRNA medications of the Tübinger company.

vaccine for the vaccine campaign

The federal government originally planned the CureVac vaccine for the vaccination campaign. CureVac also involves the federal government to 16 percent indirectly via the State Bank KfW. In this way, politics wanted to secure the company against a possible takeover from abroad. The largest share of the company holds the SAP co-founder and Investor Dietmar Hopp. The preparation of the Tübing company is a so-called mRNA vaccine - such as the BionTech / Pfizer (Germany / USA) and Moderna (USA).

On Wacker Chemie, the termination of the contract has no major impact, the Munich Group announced. For the Wacker Biosolutions division, this has no significant impact on sales and earnings development. WACKER wants to use the releasing capacities of its Dutch vaccine production for other customers. (with dpa)

Alaska's largest hospital implements crisis standards of care; Florida makes death data public after secrecy: COVID-19 updates .
Alaska’s largest hospital applies rations care, prioritizing resources to those patients who have the potential to benefit the most. COVID-19 updates.“While we are doing our utmost, we are no longer able to provide the standard of care to each and every patient who needs our help,” Dr. Kristen Solana Walkinshaw, chief of staff at Providence Alaska Medical Center, wrote in a letter addressed to Alaskans distributed Tuesday.

usr: 1
This is interesting!